PowerShares Dynamic Biotech & Genome ETF

Most Recent

  • uploads///Chart
    Earnings Report

    Seattle Genetics’ 1Q16 Earnings: What Are Analysts Expecting?

    Seattle Genetics is set to release its first-quarter 2016 earnings on April 28, 2016. Analysts estimate revenues of around $116 million for 1Q16.

    By Mike Benson
  • uploads///virus infected cells _
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Valuation on May 23

    Ionis Pharmaceuticals (IONS), a leading therapeutics company, develops and markets drugs for life-threatening diseases.

    By Mike Benson
  • uploads///Graph Autosomal recessive pattern
    Company & Industry Overviews

    BioMarin Leads in the Market for Mucopolysaccharidoses Disorders

    BioMarin holds three drugs in its portfolio indicated for different types of mucopolysaccharidoses disorders. They are Vimizim, Naglazyme, and Aldurazyme.

    By Jillian Dabney
  • uploads///Sangamo
    Company & Industry Overviews

    A Financial Overview of Sangamo Therapeutics in December 2018

    In the first nine months of 2018, Sangamo Therapeutics’ (SGMO) net revenues grew ~145% to reach $57.6 million from $23.5 million.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Amgen: Analysts’ Recommendations on October 25

    Wall Street analysts expect Amgen’s (AMGN) revenues to decrease marginally by ~0.1% to $5.769 billion during the third quarter.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    Biogen Surpassed Estimates in Q3 2018, Reports Strong Growth

    Today, Biogen (BIIB) reported EPS of $7.40 on revenues of ~$3.44 billion. BIIB beat the EPS estimate of $6.78 on revenues of ~$3.33 billion.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Biogen: Revenue Growth Is Expected in Q3

    Interferon contributed ~18% of Biogen’s total revenues. Analysts expect the revenues to decrease during the third quarter.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Stock Performance in September

    On September 28, Ionis Pharmaceuticals received one “strong buy” rating, three “buy” ratings, seven “hold” ratings, and two “sell” ratings.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What Analysts Recommend for Ionis after Q2 2018

    Wall Street analysts estimate Ionis Pharmaceuticals (IONS) will report year-over-year growth of ~34.8% in revenues to $612.5 million in 2018 as compared to revenues of $507.7 million during 2017.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analysts Are Bullish on Sarepta Therapeutics

    Sarepta Therapeutics (SRPT) reported revenues of $64.6 million and a net loss of $0.55 per share in Q1 2018.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analysts Have Mixed Opinions about Ionis

    Wall Street analysts estimate that Ionis’s (IONS) Q2 2018 revenues will rise ~30.0% to $135.5 million as compared to $104.2 million in Q2 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Ionis’s Spinraza Performed in 4Q17

    Ionis Pharmaceuticals’ (IONS) Spinraza (nusinersen) is a drug designed for the treatment of spinal muscular atrophy.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Exploring Ionis’s 3Q17 Quarterly Revenue Trend

    Ionis’s revenue sources include its commercial revenue and its research and development revenue under its collaborative agreements.

    By Mike Benson
  • uploads///Chart  HIV HBV
    Company & Industry Overviews

    Gilead’s HIV and Hepatitis B Portfolio in 3Q17

    Gilead’s portfolio As discussed previously, Gilead Sciences’ (GILD) portfolio includes antiviral drugs and other drugs. Whereas its antiviral products include those for hepatitis C, HIV, and hepatitis B infections, its other drugs include oncology, cardiovascular, inflammation, respiratory, and other products. HIV and hepatitis B products The above chart compares revenue for key HIV and hepatitis B products, which include […]

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Myriad Genetics Saw Positive Results from GeneSight Trial

    Myriad Genetics (MYGN) announced positive results from its Impact study, which evaluated the effectiveness of the GeneSight precision medicine test.

    By Margaret Patrick
  • uploads///Chart  Harvoni
    Company & Industry Overviews

    How Did Gilead’s Blockbuster Drug Harvoni Perform in 2Q17?

    Harvoni is the top-selling drug in Gilead Sciences’ (GILD) portfolio. The drug is used for the treatment of genotype-1 hepatitis C virus (or HCV) infection.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What’s Ionis Pharmaceuticals’ Valuation?

    Ionis Pharmaceuticals (IONS) has been one of the leading pharmaceutical companies in the RNA-targeted therapeutic space for over 26 years.

    By Mike Benson
  • uploads///Chart  BIIB
    Miscellaneous

    What Drove Biogen Stock in 2Q17?

    Biogen (BIIB) stock has risen ~0.40% in 2Q17 and ~4.1% year-to-date as of July 7, 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Incyte’s Valuation Has Changed since 1Q17 Results

    Incyte reported revenues of $384.1 million in 1Q17 as compared to $263.5 million in 1Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Changes in Ionis Pharmaceuticals’ Valuation after 1Q17

    In 1Q17, Ionis Pharmaceuticals reported EPS (earnings per share) of $0.03 on revenue of $110.3 million, compared with EPS of -$0.52 on revenue of $36.9 million in 1Q16. In this series, we’ll look at its valuation since 1Q17.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at Incyte’s Product Portfolio

    Incyte has classified its oncology product portfolio into targeted anti-cancer therapies and immuno-oncology or immunotherapies.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What’s in Incyte’s Product Portfolio?

    Incyte’s (INCY) product portfolio includes drugs for oncology as well as other areas.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Neurocrine Biosciences Pursues Women’s Health Segment with Elagolix

    While Neurocrine Biosciences (NBIX) invented and developed Elagolix until Phase 2 trials, it is currently being tested in Phase 3 trials by AbbVie (ABBV).

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    How Did Gilead’s Other Products Perform in 2Q16?

    Gilead’s oncology portfolio includes Zydelig, which is used in combination with rituximab for the treatment of chronic lymphocytic leukemia (or CLL).

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Incyte’s Product Portfolio Includes Potentially Lucrative Drugs

    Incyte’s (INCY) product portfolio includes drugs for oncology as well as non-oncology. It includes targeted therapies as well as immunotherapies.

    By Mike Benson
  • uploads///Share price
    Company & Industry Overviews

    Why Did BioMarin’s Share Price Tank after Brexit?

    After the UK’s decision to withdraw from the EU, a sudden shock hit global markets on June 24. BioMarin lost ~11% of its value in the subsequent two days.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Inside Neurocrine Biosciences’ Analyst Recommendations in 2016

    Based on the recommendations of eight brokerage firms, a Bloomberg survey reported that 100% of analysts gave Neurocrine Biosciences “buy” recommendations.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    An Inside Look at Incyte’s Product Portfolio

    Incyte’s (INCY) product portfolio includes drugs for oncology as well as non-oncology. For oncology, its product portfolio includes targeted therapies as well as immunotherapies.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Does Incyte’s Valuation Compare to Its Peers?

    In this series, we’ll look at the performance of Incyte’s existing products and other factors that are driving the company’s revenues and valuation.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What Can We Expect from Seattle Genetics’s Adcetris in 1Q16?

    Adcetris is an anti-CD30 monoclonal antibody that targets CD30, which is a marker for lymphoma.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Does Incyte’s Valuation Compare to Peers?

    Incyte, a Delaware-based biopharmaceutical company, is focused on developing and commercializing oncology products to cater to unmet medical needs.

    By Mike Benson
  • uploads///Vimizim
    Company & Industry Overviews

    BioMarin’s Vimizim Sales Were up by 195% in 2015

    Vimizim contributed 26% to the top line of BioMarin Pharmaceutical in 2015. Meanwhile, the number of patients on Vimizim rose by 10% during 4Q15 over 3Q15.

    By Jillian Dabney
  • uploads///chart
    Macroeconomic Analysis

    Outlook for PBE’s Biotechnology Subsectors

    PBE’s biotechnology subsector is trading below its 100-day moving average by 3.0%, but above it 20-day and 50-day averages by 1.3% and 4.0%, respectively.

    By Ivan Kading
  • uploads///Chart
    Macroeconomic Analysis

    The PowerShares Dynamic Pharmaceuticals ETF: PJP’s 2015 Performance

    As of November 2015, PJP has outperformed the market, with a YTD return of 6.5%. The fund’s top ten holdings represent 52.41% of its total portfolio.

    By Ivan Kading
  • uploads///Chart
    Macroeconomic Analysis

    PJP and PBE Are Sectoral Smart Beta Funds

    The PowerShares Dynamic Pharmaceuticals Portfolio ETF (PJP) is a smart beta fund that tracks the performance of the Dynamic Pharmaceutical Intellidex Index.

    By Ivan Kading
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.